An observational study in Intraocular Inflammation and Intravitreal Injections, sponsored by Copenhagen University Hospital, Rigshospitalet. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Copenhagen University Hospital, Rigshospitalet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg. Phase 3 trials supported its use in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
The aim of this study was to estimate the incidence of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injections in an unselected cohort treated at a large tertiary referral center, and describe the presentation, management and outcome of the affected eyes.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
This study's enrollment of 3,690 is above the median of 114 across 105 observational studies indexed under Uveitis.
Browse Uveitis studies →Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients who received at least 1 intravitreal aflibercept 8mg injection between 01/DEC/2024 and 30/NOV/2025 at the Department of Ophthalmology, Rigshospitalet, Denmark
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Aflibercept (Eylea)
intravitreal injection
Also known as: aflibercept 8mg
Incidence of IOI following an intravitreal aflibercept 8 mg injection
Reported per patient, per eye and per injection
Time frame: 01/DEC/2024 - 30/NOV/2025
Anatomical IOI phenotype
Described after the SUN classification system
Time frame: 01/DEC/2024 - 30/NOV/2025
Time from injection to IOI symptom onset
Described in days
Time frame: 01/DEC/2024 - 30/NOV/2025
Disease duration of IOI
Described in days
Time frame: 01/DEC/2024 - 30/NOV/2025
Treatment strategy after the IOI event
Description of the type of drug or intervention used
Time frame: 01/DEC/2024 - 30/NOV/2025
Functional outcome after the IOI event
Described in logMAR best-corrected visual acuity
Time frame: 01/DEC/2024 - 30/NOV/2025
Comparisons by demographic characteristics, diagnosis and treatment status
Described as exploratory descriptive analysis
Time frame: 01/DEC/2024 - 30/NOV/2025
Plan to share: No — Raw data sharing with third parties was not approved for this project.
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Aug 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Rigshospitalet